Evidence map›Paper›PMID 32905943›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2020

Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities.

Minna Rahnasto-Rilla, Joni Järvenpää, Marjo Huovinen, Anna-Mari Schroderus, Emmi-Leena Ihantola, Jenni Küblbeck, Mohammed Khadeer, Ruin Moaddel, Maija Lahtela-Kakkonen

Open access · goldAbstract read
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Minna Rahnasto-RillaSchool of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland. Electronic address: minna.rahnasto@uef.fi.
Joni JärvenpääSchool of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland.
Marjo HuovinenSchool of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland.
Anna-Mari SchroderusDepartment of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Emmi-Leena IhantolaDepartment of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Jenni KüblbeckSchool of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland.
Mohammed KhadeerBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 21224, USA.
Ruin MoaddelBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 21224, USA. Electronic address: moaddelru@grc.nia.nih.gov.
Maija Lahtela-KakkonenSchool of Pharmacy, University of Eastern Finland, 70210, Kuopio, Finland. Electronic address: maija.lahtela-kakkonen@uef.fi.
University of Eastern Finland · FINational Institutes of Health · US

Funding

Immobilized Receptors In Drug DiscoveryZIAAG000295 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$11.4M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA AG000295NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Sirtuin 6 (SIRT6), a member of sirtuin family (SIRT1-7), regulates distinct cellular functions; genome stability, DNA repair, and inflammation related diseases. Recently, we demonstrated that anthocyanidins in berries induce the catalytic activity of SIRT6. In this study, we explored the effects of Galloflavin and Ellagic acid, the most common polyphenols in berries, on SIRT6. SIRT6 deacetylation was investigated using HPLC and immunoblotting assays. The expression levels of SIRT6, glycolytic proteins and cellular metabolism were studied on human colon adenocarcinoma cells (Caco2). Molecular docking studies were carried out to study possible interactions of the compounds with sirtuins. Ellagic acid increased the deacetylase activity of SIRT6 by up to 50-fold; it showed moderate inhibition of SIRT1-3. Galloflavin and Ellagic acid showed anti-proliferative effects on Caco2. The compounds also upregulated SIRT6 expression whereas key proteins in glycolysis were downregulated. Galloflavin decreased glucose transporter 1 (GLUT1) expression, and Ellagic acid affected the expression of protein dehydrogenase kinase 1 (PDK1). Interestingly, both compounds caused reduction in glucose uptake and lactate production. Both Galloflavin and Ellagic acid were able to form hydrogen bonds with Asp188 and Gly6 in SIRT6. In this study, we showed that Galloflavin and Ellagic acid increased SIRT6 activity and decreased the expression of SIRT6 associated proteins involved in cancer development. Taken together, Galloflavin and Ellagic acid targeting SIRT6 activity may provide a new insight in the development of anti-cancer therapy.

Indexed as

AcetylationAntineoplastic AgentsCaco-2 CellsEllagic AcidGlucoseGlucose Transporter Type 1HumansIsocoumarinsMolecular Docking SimulationPyruvate Dehydrogenase Acetyl-Transferring KinaseSirtuinsAntineoplastic AgentsEllagic AcidgalloflavinGlucoseGlucose Transporter Type 1IsocoumarinsPDK1 protein, humanPyruvate Dehydrogenase Acetyl-Transferring KinaseSIRT6 protein, humanSirtuinsSLC2A1 protein, humanBerriesCancerPolyphenolSirtuinTannin

Identifiers

PMID32905943
PMCPMC12036747
OpenAlexW3083749662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.